REDUCED-TOXICITY MYELOABLATIVE TBI-BASED CONDITIONING FOR ≥2-MISMATCH PARTIALLY MATCHED RELATED DONOR HSCT WITH PTCY IN HIGH-RISK HEMATOLOGICAL MALIGNANCIES: SINGLE-CENTRE REAL-WORLD OUTCOMES FROM INDIA (EBMT 2026) - Feb 7, 2026 - Abstract #P064; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "Background: Partially matched related donor (PMRD) HSCT with post-transplant cyclophosphamide (PTCy) broadens access to allogeneic transplantation...Conditioning comprised fludarabine–TBI 8 Gy (predominantly ALL) and fludarabine–melphalan 75 mg/m²–TBI 4 Gy...Program specific modifications adapted from earlier clinical experience of program leads included (i) early UGIE for upper-GI symptoms enabling prompt diagnosis of predominantly upper-GI aGVHD, (ii) planned early immunosuppression taper/withdrawal (typically by ~day 60) to augment graft-versus-leukemia effect, (iii) universal prophylactic/pre-emptive granulocyte transfusions for all patients, and (iv) a resource-adapted CMV strategy with off-label leflunomide-based pre-emptive management for low-level CMV DNAemia before letermovir availability...CMV reactivation occurred in 5/10 and BK virus in 2/10; TA-TMA occurred in 1/10 (resolved with Rituximab , Narsoplimab) and VOD/SOS in 0/10... An RT-MAC..."
Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology
|
|
Prashant Mehta1; Ankita Singh1; Rahul Kumar1; Anshul Jain1; Nupur Das1; Pravas Chandra Mishra1; Saphalta Baghmar1; Vidit Kapoor1; Kusum Gupta1; Swati Pabbi1; Rahul Katharia1; Jagsahib Kaur1
|